The content on this page is designed for Australia. Check courses designed for Canada (EN)

This course has expired. View available courses.

Oncology, Dermatology

The new era of adjuvant immunotherapy for patients with completely resected stage III/IV melanoma

Australia has one of the highest rates of melanoma in the world and as a result, it is often referred to as 'Australia's national cancer'. Skin GPs and Dermatologists play an important role in identifying suspected melanoma and referring patients for assessment and treatment. In the new era of adjuvant immunotherapies for completely resected Stage III/IV melanoma, sentinel lymph node biopsy (SLNB) plays an important role in determining whether patients are eligible for therapy.

This 1-hour RACGP accredited activity aims to equip Skin GPs and Dermatologists with the information they need to assist oncologists in ensuring that eligible patients with completely resected Stage III/IV melanoma have access to adjuvant immunotherapy and are supported throughout their treatment.

It features two cases studies and expert video interviews from the multidisciplinary faculty.


This program is supported by an independent educational grant provided from Bristol Myers Squibb.

DURATION

1 hr

PROFESSION

Physician

# OF CREDITS

2

ACCREDITATION

RACGP CPD Program

EXPIRY DATE

2022-12-31

Australia has one of the highest rates of melanoma in the world and as a result, it is often referred to as ‘Australia’s national cancer’. Skin GPs and Dermatologists play an important role in identifying suspected melanoma and referring patients for assessment and treatment. In the new era of adjuvant immunotherapies for completely resected Stage III/IV melanoma, sentinel lymph node biopsy (SLNB) plays an important role in determining whether patients are eligible for therapy.

This 1-hour RACGP accredited activity aims to equip Skin GPs and Dermatologists with the information they need to assist oncologists in ensuring that eligible patients with completely resected Stage III/IV melanoma have access to adjuvant immunotherapy and are supported throughout their treatment.

It features two cases studies and expert video interviews from the multidisciplinary faculty.


This program is supported by an independent educational grant provided from Bristol Myers Squibb.

Faculty

A/Prof Victoria Atkinson,
Medical Oncologist, Senior Staff Specialist, Princess Alexandra Hospital, QLD

Prof Andrew Barbour,
Senior General Surgeon, Greenslopes and Mater Private Hospitals, Princess Alexandra Hospital, QLD

Dr Lisa Beecham,
General Practitioner, Robina Town Medical Centre, QLD

Dr Dougal Coates,
Dermatologist, Clayfield Dermatology Specialist Centre, QLD

Learning objectives

At the conclusion of this activity, participants will be able to:

  • Describe the role of sentinel lymph node biopsy (SLNB) in identifying patients at high risk of recurrence or relapse following complete resection of melanoma, who may benefit from adjuvant immunotherapy
  • Recall the latest clinical evidence and recommendations on the role of adjuvant immunotherapy in patients with completely resected Stage III/IV melanoma 
  • Incorporate into current practice a systematic approach for identifying patients with melanoma who should be referred to a surgeon for SLNB 
  • Outline the ways in which a multidisciplinary team approach can improve outcomes for patients with melanoma

Accreditation

This Active Learning Module has been approved by RACGP CPD Program for 2 CPD points.

Activity no. 205436

Members are able to claim CPD activity points for 2 points through 'Quick log' on their RACGP CPD Dashboard.

Cost of course:  
Free
# of credits: 2
Duration: 1 hr

FAQs & HELP

MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.

All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.

The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.

Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.

MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.

Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.

No, registration with MDBriefCase is free!

To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.

If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.

Please note: if you submitted multiple password resets, only the link on the most recent email is valid.

You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.

The new era of adjuvant immunotherapy for patients with completely resected stage III/IV melanoma

1 hr

Duration

Physician

Profession

2

# of credits

Learning Objectives

At the conclusion of this activity, participants will be able to:

  • Describe the role of sentinel lymph node biopsy (SLNB) in identifying patients at high risk of recurrence or relapse following complete resection of melanoma, who may benefit from adjuvant immunotherapy
  • Recall the latest clinical evidence and recommendations on the role of adjuvant immunotherapy in patients with completely resected Stage III/IV melanoma 
  • Incorporate into current practice a systematic approach for identifying patients with melanoma who should be referred to a surgeon for SLNB 
  • Outline the ways in which a multidisciplinary team approach can improve outcomes for patients with melanoma

RACGP CPD Program

ACCREDITATION

Oncology, Dermatology

Learning Category

General

Topic

0

Price

2022-12-31

Expiry Date

AUS

Region/Language

Course Description

Australia has one of the highest rates of melanoma in the world and as a result, it is often referred to as ‘Australia’s national cancer’. Skin GPs and Dermatologists play an important role in identifying suspected melanoma and referring patients for assessment and treatment. In the new era of adjuvant immunotherapies for completely resected Stage III/IV melanoma, sentinel lymph node biopsy (SLNB) plays an important role in determining whether patients are eligible for therapy.

This 1-hour RACGP accredited activity aims to equip Skin GPs and Dermatologists with the information they need to assist oncologists in ensuring that eligible patients with completely resected Stage III/IV melanoma have access to adjuvant immunotherapy and are supported throughout their treatment.

It features two cases studies and expert video interviews from the multidisciplinary faculty.


This program is supported by an independent educational grant provided from Bristol Myers Squibb.

Faculty

A/Prof Victoria Atkinson,
Medical Oncologist, Senior Staff Specialist, Princess Alexandra Hospital, QLD

Prof Andrew Barbour,
Senior General Surgeon, Greenslopes and Mater Private Hospitals, Princess Alexandra Hospital, QLD

Dr Lisa Beecham,
General Practitioner, Robina Town Medical Centre, QLD

Dr Dougal Coates,
Dermatologist, Clayfield Dermatology Specialist Centre, QLD

Accreditation

This Active Learning Module has been approved by RACGP CPD Program for 2 CPD points.

Activity no. 205436

Members are able to claim CPD activity points for 2 points through ‘Quick log’ on their RACGP CPD Dashboard.